Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Cancer cells may use high blood sugar to build a thick, sugar-rich coating that hides them from immune attack. Researchers at Sanford Burnham Prebys found that hyperglycemia thickens this protective layer — called the glycocalyx — through a protein called HSF1. Targeting HSF1 could strip away this shield and make cancer cells easier to destroy, potentially boosting immunotherapy responses.
Cancer cells are sneaky, and it turns out high blood sugar might be giving them an extra edge. Researchers at Sanford Burnham Prebys and collaborating institutions across North America have discovered that elevated glucose levels can thicken a sugar-rich coating on cancer cell surfaces — called the glycocalyx — helping tumors evade immune detection. The findings, published in Science Advances, reveal a plausible biological mechanism linking hyperglycemia to immune evasion in cancer.
The key player? A protein called heat shock factor 1 (HSF1), previously linked to breast cancer progression. The team found that hyperglycemia only enhanced immune evasion when HSF1 was present and cells were grown under conditions mimicking the tumor microenvironment. This suggests that drugs targeting HSF1 could thin the glycocalyx, making cancer cells more visible — and vulnerable — to the immune system.
Key Takeaways:
Why it matters: With metabolic syndrome and type 2 diabetes on the rise, hyperglycemia is an increasingly common feature in cancer patients. This research offers a concrete mechanism — and a potential therapeutic strategy — to counteract the pro-tumor effects of high blood sugar.
